Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Not Recruiting

Trial ID: NCT00537030

Purpose

This clinical trial is studying the side effects of Erwinia asparaginase and what happens to the drug in the body in treating young patients with acute lymphoblastic leukemia who are allergic to PEG-asparaginase. Drugs used in chemotherapy, such as Erwinia asparaginase, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Official Title

Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase?; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children With Acute Lymphoblastic Leukemia (ALL)

Stanford Investigator(s)

Eligibility


Inclusion Criteria:

   - Diagnosis of acute lymphoblastic leukemia

   - Concurrently enrolled on a frontline Children's Oncology Group treatment trial (i.e.,
   COG-AALL0232 or COG-AALL0531, COG-AALL0331, or COG-AALL0434) at a participating
   institution

      - Must have 1 or more courses of asparaginase remaining to be administered on the
      treatment protocol

   - Must have had a grade ? 2 hypersensitivity reaction to PEG-asparaginase

   - No history of pancreatitis ? grade 2

   - No prior Erwinia asparaginase

Intervention(s):

other: laboratory biomarker analysis

other: pharmacological study

drug: asparaginase

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535

New Trial Alerts

Receive email alerts when trials open to patients.